Search

Your search keyword '"Tas, Michelle L."' showing total 25 results
Start Over Author "Tas, Michelle L."
25 results on '"Tas, Michelle L."'

1. Integrative analysis of neuroblastoma by single-cell RNA sequencing identifies the NECTIN2-TIGIT axis as a target for immunotherapy

Author

Wienke, Judith, Visser, Lindy L., Kholosy, Waleed M., Keller, Kaylee M., Barisa, Marta, Poon, Evon, Munnings-Tomes, Sophie, Himsworth, Courtney, Calton, Elizabeth, Rodriguez, Ana, Bernardi, Ronald, van den Ham, Femke, van Hooff, Sander R., Matser, Yvette A.H., Tas, Michelle L., Langenberg, Karin P.S., Lijnzaad, Philip, Borst, Anne L., Zappa, Elisa, Bergsma, Francisca J., Strijker, Josephine G.M., Verhoeven, Bronte M., Mei, Shenglin, Kramdi, Amira, Restuadi, Restuadi, Sanchez-Bernabeu, Alvaro, Cornel, Annelisa M., Holstege, Frank C.P., Gray, Juliet C., Tytgat, Godelieve A.M., Scheijde-Vermeulen, Marijn A., Wijnen, Marc H.W.A., Dierselhuis, Miranda P., Straathof, Karin, Behjati, Sam, Wu, Wei, Heck, Albert J.R., Koster, Jan, Nierkens, Stefan, Janoueix-Lerosey, Isabelle, de Krijger, Ronald R., Baryawno, Ninib, Chesler, Louis, Anderson, John, Caron, Hubert N., Margaritis, Thanasis, van Noesel, Max M., and Molenaar, Jan J.

Published
2024
Full Text
View/download PDF

2. Integrative analysis of neuroblastoma by single-cell RNA sequencing identifies the NECTIN2-TIGIT axis as a target for immunotherapy

Author

Afd Biomol.Mass Spect. and Proteomics, Sub Biomol.Mass Spectrometry & Proteom., Afd Pharmaceutics, Biomolecular Mass Spectrometry and Proteomics, Pharmaceutics, Wienke, Judith, Visser, Lindy L, Kholosy, Waleed M, Keller, Kaylee M, Barisa, Marta, Poon, Evon, Munnings-Tomes, Sophie, Himsworth, Courtney, Calton, Elizabeth, Rodriguez, Ana, Bernardi, Ronald, van den Ham, Femke, van Hooff, Sander R, Matser, Yvette A H, Tas, Michelle L, Langenberg, Karin P S, Lijnzaad, Philip, Borst, Anne L, Zappa, Elisa, Bergsma, Francisca J, Strijker, Josephine G M, Verhoeven, Bronte M, Mei, Shenglin, Kramdi, Amira, Restuadi, Restuadi, Sanchez-Bernabeu, Alvaro, Cornel, Annelisa M, Holstege, Frank C P, Gray, Juliet C, Tytgat, Godelieve A M, Scheijde-Vermeulen, Marijn A, Wijnen, Marc H W A, Dierselhuis, Miranda P, Straathof, Karin, Behjati, Sam, Wu, Wei, Heck, Albert J R, Koster, Jan, Nierkens, Stefan, Janoueix-Lerosey, Isabelle, de Krijger, Ronald R, Baryawno, Ninib, Chesler, Louis, Anderson, John, Caron, Hubert N, Margaritis, Thanasis, van Noesel, Max M, Molenaar, Jan J, Afd Biomol.Mass Spect. and Proteomics, Sub Biomol.Mass Spectrometry & Proteom., Afd Pharmaceutics, Biomolecular Mass Spectrometry and Proteomics, Pharmaceutics, Wienke, Judith, Visser, Lindy L, Kholosy, Waleed M, Keller, Kaylee M, Barisa, Marta, Poon, Evon, Munnings-Tomes, Sophie, Himsworth, Courtney, Calton, Elizabeth, Rodriguez, Ana, Bernardi, Ronald, van den Ham, Femke, van Hooff, Sander R, Matser, Yvette A H, Tas, Michelle L, Langenberg, Karin P S, Lijnzaad, Philip, Borst, Anne L, Zappa, Elisa, Bergsma, Francisca J, Strijker, Josephine G M, Verhoeven, Bronte M, Mei, Shenglin, Kramdi, Amira, Restuadi, Restuadi, Sanchez-Bernabeu, Alvaro, Cornel, Annelisa M, Holstege, Frank C P, Gray, Juliet C, Tytgat, Godelieve A M, Scheijde-Vermeulen, Marijn A, Wijnen, Marc H W A, Dierselhuis, Miranda P, Straathof, Karin, Behjati, Sam, Wu, Wei, Heck, Albert J R, Koster, Jan, Nierkens, Stefan, Janoueix-Lerosey, Isabelle, de Krijger, Ronald R, Baryawno, Ninib, Chesler, Louis, Anderson, John, Caron, Hubert N, Margaritis, Thanasis, van Noesel, Max M, and Molenaar, Jan J

Published
2024

3. Integrative analysis of neuroblastoma by single-cell RNA sequencing identifies the NECTIN2-TIGIT axis as a target for immunotherapy

Author

CTI Nierkens, Cancer, Infection & Immunity, CTI Research, Pathologie Pathologen staf, Onderzoek Beeld, Wienke, Judith, Visser, Lindy L, Kholosy, Waleed M, Keller, Kaylee M, Barisa, Marta, Poon, Evon, Munnings-Tomes, Sophie, Himsworth, Courtney, Calton, Elizabeth, Rodriguez, Ana, Bernardi, Ronald, van den Ham, Femke, van Hooff, Sander R, Matser, Yvette A H, Tas, Michelle L, Langenberg, Karin P S, Lijnzaad, Philip, Borst, Anne L, Zappa, Elisa, Bergsma, Francisca J, Strijker, Josephine G M, Verhoeven, Bronte M, Mei, Shenglin, Kramdi, Amira, Restuadi, Restuadi, Sanchez-Bernabeu, Alvaro, Cornel, Annelisa M, Holstege, Frank C P, Gray, Juliet C, Tytgat, Godelieve A M, Scheijde-Vermeulen, Marijn A, Wijnen, Marc H W A, Dierselhuis, Miranda P, Straathof, Karin, Behjati, Sam, Wu, Wei, Heck, Albert J R, Koster, Jan, Nierkens, Stefan, Janoueix-Lerosey, Isabelle, de Krijger, Ronald R, Baryawno, Ninib, Chesler, Louis, Anderson, John, Caron, Hubert N, Margaritis, Thanasis, van Noesel, Max M, Molenaar, Jan J, CTI Nierkens, Cancer, Infection & Immunity, CTI Research, Pathologie Pathologen staf, Onderzoek Beeld, Wienke, Judith, Visser, Lindy L, Kholosy, Waleed M, Keller, Kaylee M, Barisa, Marta, Poon, Evon, Munnings-Tomes, Sophie, Himsworth, Courtney, Calton, Elizabeth, Rodriguez, Ana, Bernardi, Ronald, van den Ham, Femke, van Hooff, Sander R, Matser, Yvette A H, Tas, Michelle L, Langenberg, Karin P S, Lijnzaad, Philip, Borst, Anne L, Zappa, Elisa, Bergsma, Francisca J, Strijker, Josephine G M, Verhoeven, Bronte M, Mei, Shenglin, Kramdi, Amira, Restuadi, Restuadi, Sanchez-Bernabeu, Alvaro, Cornel, Annelisa M, Holstege, Frank C P, Gray, Juliet C, Tytgat, Godelieve A M, Scheijde-Vermeulen, Marijn A, Wijnen, Marc H W A, Dierselhuis, Miranda P, Straathof, Karin, Behjati, Sam, Wu, Wei, Heck, Albert J R, Koster, Jan, Nierkens, Stefan, Janoueix-Lerosey, Isabelle, de Krijger, Ronald R, Baryawno, Ninib, Chesler, Louis, Anderson, John, Caron, Hubert N, Margaritis, Thanasis, van Noesel, Max M, and Molenaar, Jan J

Published
2024

4. Case series on clinical applications of liquid biopsy in pediatric solid tumors: towards improved diagnostics and disease monitoring

Author

Gelineau, Nina U., primary, van Barneveld, Astrid, additional, Samim, Atia, additional, Van Zogchel, Lieke, additional, Lak, Nathalie, additional, Tas, Michelle L., additional, Matser, Yvette, additional, Mavinkurve-Groothuis, Annelies M. C., additional, van Grotel, Martine, additional, Zsiros, Jószef, additional, van Eijkelenburg, Natasha K. A., additional, Knops, Rutger R. G., additional, van Ewijk, Roelof, additional, Langenberg, Karin P. S., additional, Krijger, Ronald De, additional, Hiemcke-Jiwa, Laura S., additional, Van Paemel, Ruben, additional, Cornelli, Lotte, additional, De Preter, Katleen, additional, De Wilde, Bram, additional, Van Der Schoot, Ellen, additional, and Tytgat, Godelieve, additional

Published
2023
Full Text
View/download PDF

5. Refractory Stage M Ganglioneuroblastoma With Bone Metastases and a Favorable, Chronic Course of Disease: Description of a Patient Cohort

Author

Tas, Michelle L, Molenaar, Jan J, Peek, Annemarie M L, Lequin, Maarten H, Verdijk, Rob M, de Krijger, Ronald R, Tytgat, Godelieve A M, van Noesel, Max M, Tas, Michelle L, Molenaar, Jan J, Peek, Annemarie M L, Lequin, Maarten H, Verdijk, Rob M, de Krijger, Ronald R, Tytgat, Godelieve A M, and van Noesel, Max M

Abstract

Refractory stage M neuroblastoma (NB) is associated with a poor prognosis and a progressive course of disease. Here, we describe a unique group of patients with a discrepant clinical course. Seven histologically confirmed ganglioneuroblastoma (GNB) (n=6) and differentiating NB (n=1) patients were identified who were diagnosed with stage M disease based on iodine-123-metaiodobenzylguanidine avid bone metastases. Six patients started on high-risk treatment, without tumor response (stable disease). Treatment was discontinued before the start of consolidation treatment because of refractory response in all patients. Unexpectedly, after cessation of treatment no progression of disease occurred. In 2 patients, the primary tumors expanded (>25%) very slowly during 1.5 and 3 years, and remained stable thereafter. Metabolically, a slow decrease of urinary homovanillic acid and vanillylmandelic acid levels and iodine-123-metaiodobenzylguanidine avidity was observed. All patients are alive with presence of metastatic disease after a median follow-up of 17 years (range: 6.7 to 27 y). Interestingly, at diagnosis, 6 patients were asymptomatic, 6 patients had GNB morphology, and 5 patients had meningeal metastases. These are all features seen in only a small minority of stage M patients. This GNB entity illustrates the clinical heterogeneity of neuroblastic tumors and can be used to further study the developmental origin of different NB subtypes.

Published
2022

6. Refractory Stage M Ganglioneuroblastoma With Bone Metastases and a Favorable, Chronic Course of Disease: Description of a Patient Cohort

Author

Afd Pharmaceutics, Pharmaceutics, Tas, Michelle L, Molenaar, Jan J, Peek, Annemarie M L, Lequin, Maarten H, Verdijk, Rob M, de Krijger, Ronald R, Tytgat, Godelieve A M, van Noesel, Max M, Afd Pharmaceutics, Pharmaceutics, Tas, Michelle L, Molenaar, Jan J, Peek, Annemarie M L, Lequin, Maarten H, Verdijk, Rob M, de Krijger, Ronald R, Tytgat, Godelieve A M, and van Noesel, Max M

Published
2022

7. Refractory Stage M Ganglioneuroblastoma with Bone Metastases and a Favorable, Chronic Course of Disease:Description of a Patient Cohort

Author

Tas, Michelle L., Molenaar, Jan J., Peek, Annemarie M.L., Lequin, Maarten H., Verdijk, Rob M., de Krijger, Ronald R., Tytgat, Godelieve A.M., van Noesel, Max M., Tas, Michelle L., Molenaar, Jan J., Peek, Annemarie M.L., Lequin, Maarten H., Verdijk, Rob M., de Krijger, Ronald R., Tytgat, Godelieve A.M., and van Noesel, Max M.

Abstract

Refractory stage M neuroblastoma (NB) is associated with a poor prognosis and a progressive course of disease. Here, we describe a unique group of patients with a discrepant clinical course. Seven histologically confirmed ganglioneuroblastoma (GNB) (n = 6) and differentiating NB (n = 1) patients were identified who were diagnosed with stage M disease based on iodine-123-metaiodobenzylguanidine avid bone metastases. Six patients started on high-risk treatment, without tumor response (stable disease). Treatment was discontinued before the start of consolidation treatment because of refractory response in all patients. Unexpectedly, after cessation of treatment no progression of disease occurred. In 2 patients, the primary tumors expanded (> 25%) very slowly during 1.5 and 3 years, and remained stable thereafter. Metabolically, a slow decrease of urinary homovanillic acid and vanillylmandelic acid levels and iodine-123-metaiodobenzylguanidine avidity was observed. All patients are alive with presence of metastatic disease after a median follow-up of 17 years (range: 6.7 to 27 y). Interestingly, at diagnosis, 6 patients were asymptomatic, 6 patients had GNB morphology, and 5 patients had meningeal metastases. These are all features seen in only a small minority of stage M patients. This GNB entity illustrates the clinical heterogeneity of neuroblastic tumors and can be used to further study the developmental origin of different NB subtypes.

Published
2022

8. Refractory Stage M Ganglioneuroblastoma With Bone Metastases and a Favorable, Chronic Course of Disease: Description of a Patient Cohort

Author

MS Radiologie, Circulatory Health, Pathologie Pathologen staf, Tas, Michelle L, Molenaar, Jan J, Peek, Annemarie M L, Lequin, Maarten H, Verdijk, Rob M, de Krijger, Ronald R, Tytgat, Godelieve A M, van Noesel, Max M, MS Radiologie, Circulatory Health, Pathologie Pathologen staf, Tas, Michelle L, Molenaar, Jan J, Peek, Annemarie M L, Lequin, Maarten H, Verdijk, Rob M, de Krijger, Ronald R, Tytgat, Godelieve A M, and van Noesel, Max M

Published
2022

9. Anti-GD2 Based Immunotherapy Prevents Late Events in High-Risk Neuroblastoma Patients over 18 Months at Diagnosis

Author

Tas, Michelle L., primary, Dootjes, Lisa W., additional, Fiocco, Marta, additional, de Krijger, Ronald R., additional, Dierselhuis, Miranda P., additional, van Eijkelenburg, Natasha K. A., additional, van Grotel, Martine, additional, Kraal, Kathelijne C. J. M., additional, Peek, Annemarie M. L., additional, Tytgat, Godelieve A. M., additional, and van Noesel, Max M., additional

Published
2021
Full Text
View/download PDF

10. Tumor to normal single-cell mRNA comparisons reveal a pan-neuroblastoma cancer cell

Author

Kildisiute, Gerda, Kholosy, Waleed M, Young, Matthew D, Roberts, Kenny, Elmentaite, Rasa, van Hooff, Sander R, Pacyna, Clarissa N, Khabirova, Eleonora, Piapi, Alice, Thevanesan, Christine, Bugallo-Blanco, Eva, Burke, Christina, Mamanova, Lira, Keller, Kaylee M, Langenberg-Ververgaert, Karin P S, Lijnzaad, Philip, Margaritis, Thanasis, Holstege, Frank C P, Tas, Michelle L, Wijnen, Marc H W A, van Noesel, Max M, Del Valle, Ignacio, Barone, Giuseppe, van der Linden, Reinier, Duncan, Catriona, Anderson, John, Achermann, John C, Haniffa, Muzlifah, Teichmann, Sarah A, Rampling, Dyanne, Sebire, Neil J, He, Xiaoling, de Krijger, Ronald R, Barker, Roger A, Meyer, Kerstin B, Bayraktar, Omer, Straathof, Karin, Molenaar, Jan J, Behjati, Sam, Kildisiute, Gerda, Kholosy, Waleed M, Young, Matthew D, Roberts, Kenny, Elmentaite, Rasa, van Hooff, Sander R, Pacyna, Clarissa N, Khabirova, Eleonora, Piapi, Alice, Thevanesan, Christine, Bugallo-Blanco, Eva, Burke, Christina, Mamanova, Lira, Keller, Kaylee M, Langenberg-Ververgaert, Karin P S, Lijnzaad, Philip, Margaritis, Thanasis, Holstege, Frank C P, Tas, Michelle L, Wijnen, Marc H W A, van Noesel, Max M, Del Valle, Ignacio, Barone, Giuseppe, van der Linden, Reinier, Duncan, Catriona, Anderson, John, Achermann, John C, Haniffa, Muzlifah, Teichmann, Sarah A, Rampling, Dyanne, Sebire, Neil J, He, Xiaoling, de Krijger, Ronald R, Barker, Roger A, Meyer, Kerstin B, Bayraktar, Omer, Straathof, Karin, Molenaar, Jan J, and Behjati, Sam

Abstract

Neuroblastoma is a childhood cancer that resembles developmental stages of the neural crest. It is not established what developmental processes neuroblastoma cancer cells represent. Here, we sought to reveal the phenotype of neuroblastoma cancer cells by comparing cancer (n = 19,723) with normal fetal adrenal single-cell transcriptomes (n = 57,972). Our principal finding was that the neuroblastoma cancer cell resembled fetal sympathoblasts, but no other fetal adrenal cell type. The sympathoblastic state was a universal feature of neuroblastoma cells, transcending cell cluster diversity, individual patients, and clinical phenotypes. We substantiated our findings in 650 neuroblastoma bulk transcriptomes and by integrating canonical features of the neuroblastoma genome with transcriptional signals. Overall, our observations indicate that a pan-neuroblastoma cancer cell state exists, which may be attractive for novel immunotherapeutic and targeted avenues.

Published
2021

11. Tumor to normal single-cell mRNA comparisons reveal a pan-neuroblastoma cancer cell

Author

Afd Pharmaceutics, Pharmaceutics, Kildisiute, Gerda, Kholosy, Waleed M, Young, Matthew D, Roberts, Kenny, Elmentaite, Rasa, van Hooff, Sander R, Pacyna, Clarissa N, Khabirova, Eleonora, Piapi, Alice, Thevanesan, Christine, Bugallo-Blanco, Eva, Burke, Christina, Mamanova, Lira, Keller, Kaylee M, Langenberg-Ververgaert, Karin P S, Lijnzaad, Philip, Margaritis, Thanasis, Holstege, Frank C P, Tas, Michelle L, Wijnen, Marc H W A, van Noesel, Max M, Del Valle, Ignacio, Barone, Giuseppe, van der Linden, Reinier, Duncan, Catriona, Anderson, John, Achermann, John C, Haniffa, Muzlifah, Teichmann, Sarah A, Rampling, Dyanne, Sebire, Neil J, He, Xiaoling, de Krijger, Ronald R, Barker, Roger A, Meyer, Kerstin B, Bayraktar, Omer, Straathof, Karin, Molenaar, Jan J, Behjati, Sam, Afd Pharmaceutics, Pharmaceutics, Kildisiute, Gerda, Kholosy, Waleed M, Young, Matthew D, Roberts, Kenny, Elmentaite, Rasa, van Hooff, Sander R, Pacyna, Clarissa N, Khabirova, Eleonora, Piapi, Alice, Thevanesan, Christine, Bugallo-Blanco, Eva, Burke, Christina, Mamanova, Lira, Keller, Kaylee M, Langenberg-Ververgaert, Karin P S, Lijnzaad, Philip, Margaritis, Thanasis, Holstege, Frank C P, Tas, Michelle L, Wijnen, Marc H W A, van Noesel, Max M, Del Valle, Ignacio, Barone, Giuseppe, van der Linden, Reinier, Duncan, Catriona, Anderson, John, Achermann, John C, Haniffa, Muzlifah, Teichmann, Sarah A, Rampling, Dyanne, Sebire, Neil J, He, Xiaoling, de Krijger, Ronald R, Barker, Roger A, Meyer, Kerstin B, Bayraktar, Omer, Straathof, Karin, Molenaar, Jan J, and Behjati, Sam

Published
2021

12. Anti-GD2 based immunotherapy prevents late events in high-risk neuroblastoma patients over 18 months at diagnosis

Author

Tas, Michelle L., Dootjes, Lisa W., Fiocco, Marta, de Krijger, Ronald R., Dierselhuis, Miranda P., van Eijkelenburg, Natasha K.A., van Grotel, Martine, Kraal, Kathelijne C.J.M., Peek, Annemarie M.L., Tytgat, Godelieve A.M., van Noesel, Max M., Tas, Michelle L., Dootjes, Lisa W., Fiocco, Marta, de Krijger, Ronald R., Dierselhuis, Miranda P., van Eijkelenburg, Natasha K.A., van Grotel, Martine, Kraal, Kathelijne C.J.M., Peek, Annemarie M.L., Tytgat, Godelieve A.M., and van Noesel, Max M.

Abstract

Background: Anti-GD2 based immunotherapy has improved overall (OS) and event free survival (EFS) for high-risk neuroblastoma (HR-NBL) patients. Here, we evaluate the long-term efficacy of anti-GD2 immunotherapy in combination with isotretinoin, GM-CSF, and IL-2. Methods: Dutch HR-NBL patients treated with immunotherapy according to the COG-ANBL0032 protocol (n = 47) were included and compared to historical controls (n = 37) treated with single-agent isotret-inoin maintenance therapy. Survival time was calculated from start of the maintenance therapy. Results: The study and control group were similar concerning baseline characteristics. In the com-plete cohort, 5 year OS was 64±7% and 49±8% for the immunotherapy group and the control group, respectively (p = 0.16). Five year EFS was 57±7% and 41±8%, respectively (p = 0.16). In the subgroup of patients ≥ 18 months, 5-yr OS was 63±8% and 39±9, respectively (p = 0.04) and EFS 54±8% and 29±8%, respectively (p = 0.05). Landmark analysis for EFS with landmark point at 6 months after start of maintenance suggests a larger effect on the prevention of late than early events. Conclusions: This study is the first to confirm the results of the COG-ANBL0032 study in a cohort treated with a different induction regimen. Anti-GD2 immunotherapy prevents late events, most significantly in patients older than 18 months of age at diagnosis.

Published
2021

13. Anti-GD2 based immunotherapy prevents late events in high-risk neuroblastoma patients over 18 months at diagnosis

Author

Pathologie Pathologen staf, Arts-assistenten Kinderen, PMC Medisch specialisten, Onderzoek Beeld, Tas, Michelle L., Dootjes, Lisa W., Fiocco, Marta, de Krijger, Ronald R., Dierselhuis, Miranda P., van Eijkelenburg, Natasha K.A., van Grotel, Martine, Kraal, Kathelijne C.J.M., Peek, Annemarie M.L., Tytgat, Godelieve A.M., van Noesel, Max M., Pathologie Pathologen staf, Arts-assistenten Kinderen, PMC Medisch specialisten, Onderzoek Beeld, Tas, Michelle L., Dootjes, Lisa W., Fiocco, Marta, de Krijger, Ronald R., Dierselhuis, Miranda P., van Eijkelenburg, Natasha K.A., van Grotel, Martine, Kraal, Kathelijne C.J.M., Peek, Annemarie M.L., Tytgat, Godelieve A.M., and van Noesel, Max M.

Published
2021

14. Tumor to normal single-cell mRNA comparisons reveal a pan-neuroblastoma cancer cell

Author

Groep Holstege, CTI Leusen, CMM Groep Burgering, Cancer, Zorgeenheid Kinderchirurgie Medisch, Onderzoek Beeld, Pathologie Pathologen staf, Kildisiute, Gerda, Kholosy, Waleed M., Young, Matthew D., Roberts, Kenny, Elmentaite, Rasa, van Hooff, Sander R., Pacyna, Clarissa N., Khabirova, Eleonora, Piapi, Alice, Thevanesan, Christine, Bugallo-Blanco, Eva, Burke, Christina, Mamanova, Lira, Keller, Kaylee M., Langenberg-Ververgaert, Karin P.S., Lijnzaad, Philip, Margaritis, Thanasis, Holstege, Frank C.P., Tas, Michelle L., Wijnen, Marc H.W.A., van Noesel, Max M., del Valle, Ignacio, Barone, Giuseppe, van der Linden, Reinier, Duncan, Catriona, Anderson, John, Achermann, John C., Haniffa, Muzlifah, Teichmann, Sarah A., Rampling, Dyanne, Sebire, Neil J., He, Xiaoling, de Krijger, Ronald R., Barker, Roger A., Meyer, Kerstin B., Bayraktar, Omer, Straathof, Karin, Molenaar, Jan J., Behjati, Sam, Groep Holstege, CTI Leusen, CMM Groep Burgering, Cancer, Zorgeenheid Kinderchirurgie Medisch, Onderzoek Beeld, Pathologie Pathologen staf, Kildisiute, Gerda, Kholosy, Waleed M., Young, Matthew D., Roberts, Kenny, Elmentaite, Rasa, van Hooff, Sander R., Pacyna, Clarissa N., Khabirova, Eleonora, Piapi, Alice, Thevanesan, Christine, Bugallo-Blanco, Eva, Burke, Christina, Mamanova, Lira, Keller, Kaylee M., Langenberg-Ververgaert, Karin P.S., Lijnzaad, Philip, Margaritis, Thanasis, Holstege, Frank C.P., Tas, Michelle L., Wijnen, Marc H.W.A., van Noesel, Max M., del Valle, Ignacio, Barone, Giuseppe, van der Linden, Reinier, Duncan, Catriona, Anderson, John, Achermann, John C., Haniffa, Muzlifah, Teichmann, Sarah A., Rampling, Dyanne, Sebire, Neil J., He, Xiaoling, de Krijger, Ronald R., Barker, Roger A., Meyer, Kerstin B., Bayraktar, Omer, Straathof, Karin, Molenaar, Jan J., and Behjati, Sam

Published
2021

15. Immune Monitoring during Therapy Reveals Activitory and Regulatory Immune Responses in High-Risk Neuroblastoma

Author

CTI Nierkens, Cancer, Infection & Immunity, CTI UDAIR, Arts-assistenten Kinderen, PMC Medisch specialisten, Onderzoek Beeld, Regenerative Medicine and Stem Cells, Apotheek O&O&O, CDL Patiëntenzorg MI, CTI Research, Szanto, Celina L, Cornel, Annelisa M, Tamminga, Sara M, Delemarre, Eveline M, de Koning, Coco C H, van den Beemt, Denise A M H, Dunnebach, Ester, Tas, Michelle L, Dierselhuis, Miranda P, Tytgat, Lieve G A M, van Noesel, Max M, Kraal, Kathelijne C J M, Boelens, Jaap-Jan, Huitema, Alwin D R, Nierkens, Stefan, CTI Nierkens, Cancer, Infection & Immunity, CTI UDAIR, Arts-assistenten Kinderen, PMC Medisch specialisten, Onderzoek Beeld, Regenerative Medicine and Stem Cells, Apotheek O&O&O, CDL Patiëntenzorg MI, CTI Research, Szanto, Celina L, Cornel, Annelisa M, Tamminga, Sara M, Delemarre, Eveline M, de Koning, Coco C H, van den Beemt, Denise A M H, Dunnebach, Ester, Tas, Michelle L, Dierselhuis, Miranda P, Tytgat, Lieve G A M, van Noesel, Max M, Kraal, Kathelijne C J M, Boelens, Jaap-Jan, Huitema, Alwin D R, and Nierkens, Stefan

Published
2021

16. Immune Monitoring during Therapy Reveals Activitory and Regulatory Immune Responses in High-Risk Neuroblastoma

Author

Szanto, Celina L., primary, Cornel, Annelisa M., additional, Tamminga, Sara M., additional, Delemarre, Eveline M., additional, de Koning, Coco C. H., additional, van den Beemt, Denise A. M. H., additional, Dunnebach, Ester, additional, Tas, Michelle L., additional, Dierselhuis, Miranda P., additional, Tytgat, Lieve G. A. M., additional, van Noesel, Max M., additional, Kraal, Kathelijne C. J. M., additional, Boelens, Jaap-Jan, additional, Huitema, Alwin D. R., additional, and Nierkens, Stefan, additional

Published
2021
Full Text
View/download PDF

18. Tumor to normal single-cell mRNA comparisons reveal a pan-neuroblastoma cancer cell

Author

Kildisiute, Gerda, primary, Kholosy, Waleed M., additional, Young, Matthew D., additional, Roberts, Kenny, additional, Elmentaite, Rasa, additional, van Hooff, Sander R., additional, Pacyna, Clarissa N., additional, Khabirova, Eleonora, additional, Piapi, Alice, additional, Thevanesan, Christine, additional, Bugallo-Blanco, Eva, additional, Burke, Christina, additional, Mamanova, Lira, additional, Keller, Kaylee M., additional, Langenberg-Ververgaert, Karin P.S., additional, Lijnzaad, Philip, additional, Margaritis, Thanasis, additional, Holstege, Frank C.P., additional, Tas, Michelle L., additional, Wijnen, Marc H.W.A., additional, van Noesel, Max M., additional, del Valle, Ignacio, additional, Barone, Giuseppe, additional, van der Linden, Reinier, additional, Duncan, Catriona, additional, Anderson, John, additional, Achermann, John C., additional, Haniffa, Muzlifah, additional, Teichmann, Sarah A., additional, Rampling, Dyanne, additional, Sebire, Neil J., additional, He, Xiaoling, additional, de Krijger, Ronald R., additional, Barker, Roger A., additional, Meyer, Kerstin B., additional, Bayraktar, Omer, additional, Straathof, Karin, additional, Molenaar, Jan J., additional, and Behjati, Sam, additional

Published
2021
Full Text
View/download PDF

19. Tumor to normal single cell mRNA comparisons reveal a pan-neuroblastoma cancer cell

Author

Kildisiute, Gerda, primary, Kholosy, Waleed M., additional, Young, Matthew D., additional, Roberts, Kenny, additional, Elmentaite, Rasa, additional, van Hooff, Sander R., additional, Khabirova, Eleonora, additional, Piapi, Alice, additional, Thevanesan, Christine, additional, Blanco, Eva Bugallo, additional, Burke, Christina, additional, Mamanova, Lira, additional, Lijnzaad, Philip, additional, Margaritis, Thanasis, additional, Holstege, Frank C.P., additional, Tas, Michelle L., additional, Wijnen, Marc H.W.A., additional, van Noesel, Max M., additional, del Valle, Ignacio, additional, Barone, Giuseppe, additional, van der Linden, Reinier, additional, Duncan, Catriona, additional, Anderson, John, additional, Achermann, John C., additional, Haniffa, Muzlifah, additional, Teichmann, Sarah A., additional, Rampling, Dyanne, additional, Sebire, Neil J., additional, He, Xiaoling, additional, de Krijger, Ronald R., additional, Barker, Roger A., additional, Meyer, Kerstin B., additional, Bayraktar, Omer, additional, Straathof, Karin, additional, Molenaar, Jan J., additional, and Behjati, Sam, additional

Published
2020
Full Text
View/download PDF

20. Neuroblastoma stage 4S: Tumor regression rate and risk factors of progressive disease

Author

Tas, Michelle L, Nagtegaal, Michelle, Kraal, Kathelijne C J M, Tytgat, Godelieve A M, Abeling, Nico G G M, Koster, Jan, Pluijm, Saskia M F, Zwaan, C Michel, de Keizer, Bart, Molenaar, Jan J, van Noesel, Max M, UU BETA RESEARCH, Pediatrics, Graduate School, ARD - Amsterdam Reproduction and Development, AGEM - Endocrinology, metabolism and nutrition, AGEM - Digestive immunity, CCA - Cancer Treatment and Quality of Life, Paediatric Oncology, Laboratory Genetic Metabolic Diseases, and UU BETA RESEARCH

Subjects
Male, Spontaneous/pathology, medicine.medical_specialty, Neuroblastoma/pathology, Gastroenterology, Cohort Studies, Excretion, Neuroblastoma, 03 medical and health sciences, Neoplasm Regression, Spontaneous/pathology, 0302 clinical medicine, Risk Factors, Internal medicine, medicine, Humans, Stage (cooking), Retrospective Studies, business.industry, Infant, Newborn, Infant, Retrospective cohort study, Hematology, Newborn, medicine.disease, Regression, Oncology, Neoplasm Regression, Spontaneous, 030220 oncology & carcinogenesis, Pediatrics, Perinatology and Child Health, Cohort, Disease Progression, Stage 4S Neuroblastoma, Neoplasm Regression, Female, business, Progressive disease, 030215 immunology
Abstract

BACKGROUND: The clinical course of neuroblastoma stage 4S or MS is characterized by a high rate of spontaneous tumor regression and favorable outcome. However, the clinical course and rate of the regression are poorly understood. METHODS: A retrospective cohort study was performed, including all patients with stage 4S neuroblastoma without MYCN amplification, from two Dutch centers between 1972 and 2012. We investigated the clinical characteristics, the biochemical activity reflected in urinary catecholamine excretion, and radiological imaging to describe the kinetics of tumor regression, therapy response and outcome. RESULTS: The cohort of 31 patients reached a 10-year overall survival of 84% ± 7% (median follow-up 16 years; range, 3.3-39). During the regressive phase, liver size normalized in 91% of the patients and catecholamine excretion in 83%, both after a median of two months (liver size: range, 0-131; catecholamines: range, 0-158). The primary tumors completely regressed in 69% after 13 months (range, 6-73), and the liver architecture normalized in 52% after 15 months (range, 5-131). Antitumor treatment was given in 52% of the patients. Interestingly, regression rates were similar for treated and untreated patients. Four of seven patients < 4 weeks old died of rapid liver expansion and organ compression. Three patients progressed to stage 4, 3 to 13 months after diagnosis; all had persistently elevated catecholamines. CONCLUSION: Patients < 4 weeks old with neuroblastoma stage 4S are at risk of fatal outcome caused by progression of liver metastases. In other patients, tumor regression is characterized by a rapid biochemical normalization that precedes radiological regression.

Published
2019
Full Text
View/download PDF

21. Neuroblastoma stage 4S: Tumor regression rate and risk factors of progressive disease

Author

Tas, Michelle L, Nagtegaal, Michelle, Kraal, Kathelijne C J M, Tytgat, Godelieve A M, Abeling, Nico G G M, Koster, Jan, Pluijm, Saskia M F, Zwaan, C Michel, de Keizer, Bart, Molenaar, Jan J, van Noesel, Max M, Tas, Michelle L, Nagtegaal, Michelle, Kraal, Kathelijne C J M, Tytgat, Godelieve A M, Abeling, Nico G G M, Koster, Jan, Pluijm, Saskia M F, Zwaan, C Michel, de Keizer, Bart, Molenaar, Jan J, and van Noesel, Max M

Abstract

BACKGROUND: The clinical course of neuroblastoma stage 4S or MS is characterized by a high rate of spontaneous tumor regression and favorable outcome. However, the clinical course and rate of the regression are poorly understood.METHODS: A retrospective cohort study was performed, including all patients with stage 4S neuroblastoma without MYCN amplification, from two Dutch centers between 1972 and 2012. We investigated the clinical characteristics, the biochemical activity reflected in urinary catecholamine excretion, and radiological imaging to describe the kinetics of tumor regression, therapy response and outcome.RESULTS: The cohort of 31 patients reached a 10-year overall survival of 84% ± 7% (median follow-up 16 years; range, 3.3-39). During the regressive phase, liver size normalized in 91% of the patients and catecholamine excretion in 83%, both after a median of two months (liver size: range, 0-131; catecholamines: range, 0-158). The primary tumors completely regressed in 69% after 13 months (range, 6-73), and the liver architecture normalized in 52% after 15 months (range, 5-131). Antitumor treatment was given in 52% of the patients. Interestingly, regression rates were similar for treated and untreated patients. Four of seven patients < 4 weeks old died of rapid liver expansion and organ compression. Three patients progressed to stage 4, 3 to 13 months after diagnosis; all had persistently elevated catecholamines.CONCLUSION: Patients < 4 weeks old with neuroblastoma stage 4S are at risk of fatal outcome caused by progression of liver metastases. In other patients, tumor regression is characterized by a rapid biochemical normalization that precedes radiological regression.

Published
2020

22. Neuroblastoma stage 4S: Tumor regression rate and risk factors of progressive disease

Author

UU BETA RESEARCH, Tas, Michelle L, Nagtegaal, Michelle, Kraal, Kathelijne C J M, Tytgat, Godelieve A M, Abeling, Nico G G M, Koster, Jan, Pluijm, Saskia M F, Zwaan, C Michel, de Keizer, Bart, Molenaar, Jan J, van Noesel, Max M, UU BETA RESEARCH, Tas, Michelle L, Nagtegaal, Michelle, Kraal, Kathelijne C J M, Tytgat, Godelieve A M, Abeling, Nico G G M, Koster, Jan, Pluijm, Saskia M F, Zwaan, C Michel, de Keizer, Bart, Molenaar, Jan J, and van Noesel, Max M

Published
2020

23. Neuroblastoma stage 4S: Tumor regression rate and risk factors of progressive disease

Author

MS Radiologie, Cancer, Tas, Michelle L., Nagtegaal, Michelle, Kraal, Kathelijne C.J.M., Tytgat, Godelieve A.M., Abeling, Nico G.G.M., Koster, Jan, Pluijm, Saskia M.F., Zwaan, C. Michel, de Keizer, Bart, Molenaar, Jan J., van Noesel, Max M., MS Radiologie, Cancer, Tas, Michelle L., Nagtegaal, Michelle, Kraal, Kathelijne C.J.M., Tytgat, Godelieve A.M., Abeling, Nico G.G.M., Koster, Jan, Pluijm, Saskia M.F., Zwaan, C. Michel, de Keizer, Bart, Molenaar, Jan J., and van Noesel, Max M.

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results